NovoPath & RareCan Partnership

Analysing samples from tumours lies at the heart of the discovery of new forms of treatment for cancer. Rare Cancers are not an exception to this rule and one of the key objectives of RareCan is to help research teams access samples donated by patients so that they can identify new drug targets.

For further information, please visit https://www.novopath.co.uk/collaboration-between-rarecan-and-molecular-pathology-node/

Novopath RareCan Partnership

Professor Alastair Burt said, 

‘Our main aim in NovoPath is to improve health and well-being through the delivery, innovation and promotion of precision diagnostics for precision medicine. We are thrilled to be part of a long-term collaboration with RareCan in order to improve access to diagnostics for enhanced patient care in the 21st century’.

Professor Andy Hall said, 

'Rare cancers are actually quite common - and yet have worse outcomes than more common cancers.'

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn